Partners & Business Development

Cempra is focused on the clinical development of its two lead clinical anti-infective candidates, TAKSTA and solithromycin (CEM-101). TAKSTA (sodium fusidate, CEM-102) has completed Phase 2 trials in ABSSSI. We initiated a Phase II trial with TAKSTA as a treament for prosthetic joint infections.

Solithromycin is a novel, potent, orally-active fluoroketolide with a broad spectrum of activity against S. pneumoniae, including macrolide-resistant strains, atypical bacteria such as Mycoplasma and Legionella, M. avium, biodefense-relevant pathogens and Plasmodium falciparum. Solithromycin is the first macrolide since azithromycin to have the potential for both oral and IV dosing. A Phase 3 clinical trial, with the oral formulation, in moderate-to-moderately severe community acquired bacterial pneumonia has been completed, meeting both primary and secondary objectives. The IV formulation is being evaluated in a Phase 3 clinical trial.

Solithromycin, was selected from a library of over 500 macrolides licensed from Optimer Pharmaceuticals.

In addition to solithromycin, promising lead candidates for treating anti-inflammatory diseases, such as chronic obstructive pulmonary disease (COPD), late stage asthma and psoriasis, endocrine diseases and gastrointestinal motility disorders have also been identified and are available for partnering.

To explore business opportunities with Cempra, please contact:

John Bluth